Item #: 030916-2
This Advisory reviews current information on the use of sublingual and transmucosal buprenorphine for Medication-assisted Treatment (MAT) of opioid use disorder. Topics include new formulations of buprenorphine, the effectiveness and safety of buprenorphine treatment, contraindications and cautions (including medication interactions), informed consent and treatment agreements, treatment monitoring, and indications of diversion and misuse.
Published: February 2016 (12 pages)
For a downloadable PDF version, see “You may also like…” below.